| Document Date: 2013-11-26 15:13:16
Open Document File Size: 542,26 KBShare Result on Facebook
City Reference / / Company SUSPECTED ADVERSE REACTIONS / Incyte Corporation / / Currency pence / / Event FDA Phase / / Facility Laboratory Parameter Thrombocytopenia Anemia Neutropenia / / IndustryTerm vessel puncture site / food / / MedicalCondition post-essential thrombocythemia myelofibrosis / Patients developing anemia / purpura / postural dizziness / labyrinthitis / Active serious infections / petechiae / pyuria / post-polycythemia vera myelofibrosis / cystitis / headache / Laboratory Parameter Thrombocytopenia Anemia Neutropenia / herpes zoster / Carcinogenesis / urinary tract infection / Neutropenia / active tuberculosis / vertigo / thrombocytopenia / Serious infections / fungal and viral infections / primary myelofibrosis / balance disorder / AND PRECAUTIONS Thrombocytopenia / higher anemia / Infection / end stage renal disease / dizziness / Meniere’s Disease / kidney infection / Infections / Anemia / myelofibrosis / Tuberculosis / thrombocytopenia / gradual tapering / high-risk myelofibrosis / / MedicalTreatment red blood cell transfusions / Platelet transfusions / tube feeding / dialysis / blood transfusions / / Organization Concurrent administration / DOSAGE AND ADMINISTRATION / FDA / / Person Starting Dose Greater / / / Product DOSAGE FORMS AND STRENGTHS Tablets / itraconazole / ketoconazole / clarithromycin / Adverse Drug / / ProvinceOrState Connecticut / / Technology Pharmacokinetics / Pharmacodynamics / MRI / dialysis / / URL www.fda.gov/medwatch / /
SocialTag |
_______________ HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JAKAFI safely and effectively. See full prescribing information for JAKAFI.